At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Apr 6, 2005·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]) and rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349]) for HIV Infections. Completed, enrolled 20 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the safety of two recombinant HIV vaccines in HIV infected young adults on stable anti-HIV therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesPuerto Rico, United States
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2005
Study CompletionFeb 2009
TodayJul 2026
First PostedApr 6, 2005
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Posted 21.2 years ago
Interventions
rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])biological
Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])biological
Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24